Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 362

1.

Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.

Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I.

Rheumatology (Oxford). 2006 Jan;45(1):31-7.

PMID:
16287931
2.
3.

TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.

Jesus AA, Oliveira JB, Aksentijevich I, Fujihira E, Carneiro-Sampaio MM, Duarte AJ, Silva CA.

Eur J Pediatr. 2008 Dec;167(12):1421-5. doi: 10.1007/s00431-008-0685-2.

PMID:
18408954
4.

Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.

Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ.

Rheumatology (Oxford). 2004 Nov;43(11):1405-8.

PMID:
15316120
5.

The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.

Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, Dean J, Powell RJ, Kastner DL.

Medicine (Baltimore). 2002 Sep;81(5):349-68. Review.

7.

A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.

Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y, Huang M, Tamai M, Origuchi T, Kawakami A, Migita K, Motomura M, Yoshimura T, Eguchi K.

Rheumatology (Oxford). 2004 Oct;43(10):1292-9.

PMID:
15280569
8.
9.

Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.

Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF, Turner MD.

Arthritis Rheum. 2009 Feb;60(2):619-25. doi: 10.1002/art.24294.

10.

Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes.

Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, Bidwell JL, Castañer JL, Whiteford ML, Janssens-Korpola PL, Manna R, Powell RJ, Woo P, Solis P, Minden K, Frenkel J, Yagüe J, Mirakian RM, Hitman GA, McDermott MF.

Arthritis Rheum. 2003 Sep;48(9):2632-44.

11.

Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment.

Morbach H, Richl P, Stojanov S, Lohse P, Girschick HJ.

Rheumatol Int. 2009 Dec;30(2):207-12. doi: 10.1007/s00296-009-0937-0.

PMID:
19381634
12.

Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types.

Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA, Tighe PJ, Powell RJ, Todd I.

Arthritis Rheum. 2004 Aug;50(8):2651-9.

13.

A new mutation causing autosomal dominant periodic fever syndrome in a Danish family.

Weyhreter H, Schwartz M, Kristensen TD, Valerius NH, Paerregaard A.

J Pediatr. 2003 Feb;142(2):191-3.

PMID:
12584543
14.

Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line.

Rebelo SL, Amel-Kashipaz MR, Radford PM, Bainbridge SE, Fiets R, Fang J, McDermott EM, Powell RJ, Todd I, Tighe PJ.

Arthritis Rheum. 2009 Jan;60(1):269-80. doi: 10.1002/art.24147.

16.

Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.

Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy R, Meyer O, Hayem G.

Rheumatology (Oxford). 2008 Aug;47(8):1160-7. doi: 10.1093/rheumatology/ken185.

PMID:
18559374
17.

Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.

Drenth JP, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JW.

Blood. 1995 Jun 15;85(12):3586-93.

18.

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.

Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.

Br J Dermatol. 2008 Aug;159(2):322-30. doi: 10.1111/j.1365-2133.2008.08628.x.

PMID:
18503600
19.

Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis.

Gudbrandsdottir S, Bliddal H, Petri A, Terslev L, Danneskiold-Samsoe B, Bjørnhart B, Bendtzen K, Müller K.

Scand J Rheumatol. 2004;33(6):385-8.

PMID:
15794196
20.

[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].

Boms S, Sehr T, Jappe U, Enk A.

Hautarzt. 2008 Aug;59(8):653-5. doi: 10.1007/s00105-007-1451-5. German.

PMID:
18210001

Supplemental Content

Support Center